212 related articles for article (PubMed ID: 35021603)
1. Oncogenic TYK2 P760L kinase is effectively targeted by combinatorial TYK2, mTOR and CDK4/6 kinase blockade.
Woess K; Macho-Maschler S; Van Ingen Schenau DS; Butler M; Lassnig C; Valcanover D; Poelzl A; Meissl K; Maurer B; Brandstoetter T; Vogl C; Koren A; Kubicek S; Orlova A; Moriggl R; Strobl B; Sexl V; Van Leeuwen FN; Kuiper RP; Mueller M
Haematologica; 2023 Apr; 108(4):993-1005. PubMed ID: 35021603
[TBL] [Abstract][Full Text] [Related]
2. TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia.
Sanda T; Tyner JW; Gutierrez A; Ngo VN; Glover J; Chang BH; Yost A; Ma W; Fleischman AG; Zhou W; Yang Y; Kleppe M; Ahn Y; Tatarek J; Kelliher MA; Neuberg DS; Levine RL; Moriggl R; Müller M; Gray NS; Jamieson CH; Weng AP; Staudt LM; Druker BJ; Look AT
Cancer Discov; 2013 May; 3(5):564-77. PubMed ID: 23471820
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine kinase 2 and Janus kinase‒signal transducer and activator of transcription signaling and inhibition in plaque psoriasis.
Krueger JG; McInnes IB; Blauvelt A
J Am Acad Dermatol; 2022 Jan; 86(1):148-157. PubMed ID: 34224773
[TBL] [Abstract][Full Text] [Related]
4. Germline activating TYK2 mutations in pediatric patients with two primary acute lymphoblastic leukemia occurrences.
Waanders E; Scheijen B; Jongmans MC; Venselaar H; van Reijmersdal SV; van Dijk AH; Pastorczak A; Weren RD; van der Schoot CE; van de Vorst M; Sonneveld E; Hoogerbrugge N; van der Velden VH; Gruhn B; Hoogerbrugge PM; van Dongen JJ; Geurts van Kessel A; van Leeuwen FN; Kuiper RP
Leukemia; 2017 Apr; 31(4):821-828. PubMed ID: 27733777
[TBL] [Abstract][Full Text] [Related]
5. Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis.
Roskoski R
Pharmacol Res; 2023 Mar; 189():106642. PubMed ID: 36754102
[TBL] [Abstract][Full Text] [Related]
6. Novel Small Molecule Tyrosine Kinase 2 Pseudokinase Ligands Block Cytokine-Induced TYK2-Mediated Signaling Pathways.
Zhou Y; Li X; Shen R; Wang X; Zhang F; Liu S; Li D; Liu J; Li P; Yan Y; Dong P; Zhang Z; Wu H; Zhuang L; Chowdhury R; Miller M; Issa M; Mao Y; Chen H; Feng J; Li J; Bai C; He F; Tao W
Front Immunol; 2022; 13():884399. PubMed ID: 35693820
[TBL] [Abstract][Full Text] [Related]
7. Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors.
Batista A; Barata JT; Raderschall E; Sallan SE; Carlesso N; Nadler LM; Cardoso AA
Exp Hematol; 2011 Apr; 39(4):457-472.e3. PubMed ID: 21277936
[TBL] [Abstract][Full Text] [Related]
8. Constitutive JAK/STAT signaling is the primary mechanism of resistance to JAKi in TYK2-rearranged acute lymphoblastic leukemia.
Tavakoli Shirazi P; Eadie LN; Page EC; Heatley SL; Bruning JB; White DL
Cancer Lett; 2021 Aug; 512():28-37. PubMed ID: 33971281
[TBL] [Abstract][Full Text] [Related]
9. Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2).
Min X; Ungureanu D; Maxwell S; Hammarén H; Thibault S; Hillert EK; Ayres M; Greenfield B; Eksterowicz J; Gabel C; Walker N; Silvennoinen O; Wang Z
J Biol Chem; 2015 Nov; 290(45):27261-27270. PubMed ID: 26359499
[TBL] [Abstract][Full Text] [Related]
10. Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors.
Chimalakonda A; Burke J; Cheng L; Catlett I; Tagen M; Zhao Q; Patel A; Shen J; Girgis IG; Banerjee S; Throup J
Dermatol Ther (Heidelb); 2021 Oct; 11(5):1763-1776. PubMed ID: 34471993
[TBL] [Abstract][Full Text] [Related]
11. Identification and characterization of TYK2 pseudokinase domain stabilizers that allosterically inhibit TYK2 signaling.
Locke GA; Muckelbauer J; Tokarski JS; Barbieri CM; Belić S; Falk B; Tredup J; Wang YK
Methods Enzymol; 2022; 667():685-727. PubMed ID: 35525559
[TBL] [Abstract][Full Text] [Related]
12. HSP90 inhibition leads to degradation of the TYK2 kinase and apoptotic cell death in T-cell acute lymphoblastic leukemia.
Akahane K; Sanda T; Mansour MR; Radimerski T; DeAngelo DJ; Weinstock DM; Look AT
Leukemia; 2016 Jan; 30(1):219-28. PubMed ID: 26265185
[TBL] [Abstract][Full Text] [Related]
13. Tyk2 Targeting in Immune-Mediated Inflammatory Diseases.
Rusiñol L; Puig L
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834806
[TBL] [Abstract][Full Text] [Related]
14. Anti-leukaemic activity of the TYK2 selective inhibitor NDI-031301 in T-cell acute lymphoblastic leukaemia.
Akahane K; Li Z; Etchin J; Berezovskaya A; Gjini E; Masse CE; Miao W; Rocnik J; Kapeller R; Greenwood JR; Tiv H; Sanda T; Weinstock DM; Look AT
Br J Haematol; 2017 Apr; 177(2):271-282. PubMed ID: 28295194
[TBL] [Abstract][Full Text] [Related]
15. Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia.
Simioni C; Ultimo S; Martelli AM; Zauli G; Milani D; McCubrey JA; Capitani S; Neri LM
Oncotarget; 2016 Nov; 7(48):79842-79853. PubMed ID: 27821800
[TBL] [Abstract][Full Text] [Related]
16. TYK2 Variants in B-Acute Lymphoblastic Leukaemia.
Turrubiartes-Martínez E; Bodega-Mayor I; Delgado-Wicke P; Molina-Jiménez F; Casique-Aguirre D; González-Andrade M; Rapado I; Camós M; Díaz-de-Heredia C; Barragán E; Ramírez-Orellana M; Aguado B; Figuera Á; Martínez-López J; Fernández-Ruiz E
Genes (Basel); 2020 Nov; 11(12):. PubMed ID: 33260630
[TBL] [Abstract][Full Text] [Related]
17. Healthy CD4+ T lymphocytes are not affected by targeted therapies against the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia.
Alameen AA; Simioni C; Martelli AM; Zauli G; Ultimo S; McCubrey JA; Gonelli A; Marisi G; Ulivi P; Capitani S; Neri LM
Oncotarget; 2016 Aug; 7(34):55690-55703. PubMed ID: 27494886
[TBL] [Abstract][Full Text] [Related]
18. Deucravacitinib, a tyrosine kinase 2 pseudokinase inhibitor, protects human EndoC-βH1 β-cells against proinflammatory insults.
Dos Santos RS; Guzman-Llorens D; Perez-Serna AA; Nadal A; Marroqui L
Front Immunol; 2023; 14():1263926. PubMed ID: 37854597
[TBL] [Abstract][Full Text] [Related]
19. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
Hales EC; Taub JW; Matherly LH
Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
[TBL] [Abstract][Full Text] [Related]
20. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma.
Pene F; Claessens YE; Muller O; Viguié F; Mayeux P; Dreyfus F; Lacombe C; Bouscary D
Oncogene; 2002 Sep; 21(43):6587-97. PubMed ID: 12242656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
